Blueprint Medicines Corp (BPMC)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$104.68
Buy
$105.17
$0.035 (+0.03%)
Prices updated at 16 Jan 2025, 19:40 EST
| Prices minimum 15 mins delay
Prices in USD
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. Its drug candidates include avapritinib, BLU 554, BLU-782 and BLU-667.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
Year | Gross margin (%) |
|---|---|
| 2023 | 96.58 |
| 2022 | 91.27 |
| 2021 | 90.04 |
| 2020 | 99.95 |
| 2019 | 100.00 |
| 2018 | 100.00 |
| 2017 | - |
| 2016 | - |
Valuation data table
Year | Price / Sales |
|---|---|
| 2025 | 15.01 |
| 2024 | 12.48 |
| 2023 | 25.73 |
| 2022 | 9.56 |
| 2021 | 58.29 |
| 2020 | 7.46 |
| 2019 | 232.74 |
| 2018 | 51.23 |
| 2017 | 95.75 |
| 2016 | 30.80 |
| 2015 | - |
Price/Forward earnings (YTD)
-200.00
Returns
Debt profile
Returns data table
Year | Return on assets (%) |
|---|---|
| 2023 | -42.26 |
| 2022 | -42.85 |
| 2021 | -43.36 |
| 2020 | 25.88 |
| 2019 | -55.73 |
| 2018 | -37.69 |
| 2017 | -29.67 |
| 2016 | -31.40 |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2023 | 8.03 |
| 2022 | 2.62 |
| 2021 | 1.29 |
| 2020 | 1.17 |
| 2019 | 1.52 |
| 2018 | 1.29 |
| 2017 | 1.15 |
| 2016 | 1.33 |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
